4SC AG ROCE
Was ist das ROCE von 4SC AG?
ROCE von 4SC AG ist -49.47%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit roce ähnlich 4SC AG
- Unilock Capital hat ROCE von -49.86%
- DSS Inc hat ROCE von -49.79%
- Genasys Inc hat ROCE von -49.78%
- Hookipa Pharma Inc hat ROCE von -49.72%
- Choom hat ROCE von -49.69%
- ANGLE Plc hat ROCE von -49.52%
- 4SC AG hat ROCE von -49.47%
- Beyond Meat Inc hat ROCE von -49.46%
- ProMIS Neurosciences hat ROCE von -49.45%
- Shineco Inc hat ROCE von -49.44%
- Calliditas Therapeutics AB (publ) hat ROCE von -49.42%
- AUX Resources hat ROCE von -49.38%
- Argenica Therapeutics hat ROCE von -49.26%